{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T05:00:12Z","timestamp":1783486812616,"version":"3.55.0"},"reference-count":41,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Toxicon"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.toxicon.2025.108928","type":"journal-article","created":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T07:44:23Z","timestamp":1764143063000},"page":"108928","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["If accessory proteins dissociate, why Don't toxins behave the same? multiscale simulation shows divergent in silico profiles despite an identical core neurotoxin"],"prefix":"10.1016","volume":"270","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8443-8338","authenticated-orcid":false,"given":"Eqram","family":"Rahman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2907-4746","authenticated-orcid":false,"given":"Alain","family":"Michon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parinitha","family":"Rao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Munim","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Woffles TL.","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-5801-2105","authenticated-orcid":false,"given":"John H.","family":"Joseph","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean DA.","family":"Carruthers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William Richard","family":"Webb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.toxicon.2025.108928_bib1","doi-asserted-by":"crossref","DOI":"10.1097\/DSS.0000000000004284","article-title":"Botulinum toxin accessory proteins: are they just an accessory?","author":"Avelar","year":"2024","journal-title":"Dermatol. Surg."},{"key":"10.1016\/j.toxicon.2025.108928_bib2","doi-asserted-by":"crossref","DOI":"10.1097\/DSS.0000000000001903","article-title":"Efficacy and safety of PrabotulinumtoxinA for the treatment of glabellar lines in adult subjects: results from 2 identical phase III studies","volume":"45","author":"Beer","year":"2019","journal-title":"Dermatol. Surg."},{"key":"10.1016\/j.toxicon.2025.108928_bib3","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1007\/s13555-025-01458-3","article-title":"Diffusion characteristics of LetibotulinumtoxinA, OnabotulinumtoxinA, and AbobotulinumtoxinA and its impact on muscle relaxation: a randomized split-face clinical trial","volume":"15","author":"Bennek","year":"2025","journal-title":"Dermatol. Ther."},{"key":"10.1016\/j.toxicon.2025.108928_bib4","first-page":"227","article-title":"Botulinum toxin type A products are not interchangeable: a review of the evidence","volume":"8","author":"Brin","year":"2014","journal-title":"Biologics"},{"key":"10.1016\/j.toxicon.2025.108928_bib5","doi-asserted-by":"crossref","first-page":"266","DOI":"10.3390\/toxins16060266","article-title":"Update on non-interchangeability of botulinum neurotoxin products","volume":"16","author":"Brin","year":"2024","journal-title":"Toxins"},{"key":"10.1016\/j.toxicon.2025.108928_bib6","article-title":"Diffusion of botulinum toxins","volume":"2","author":"Brodsky","year":"2012","journal-title":"Tremor Other Hyperkinet Mov (N Y)"},{"key":"10.1016\/j.toxicon.2025.108928_bib7","doi-asserted-by":"crossref","DOI":"10.5334\/tohm.120","article-title":"Diffusion of botulinum toxins","volume":"2","author":"Brodsky","year":"2012","journal-title":"Tremor and Other Hyperkinetic Movements"},{"key":"10.1016\/j.toxicon.2025.108928_bib8","doi-asserted-by":"crossref","DOI":"10.5603\/PJNNS.a2021.0027","article-title":"Botulinum toxin type-A preparations are not the same medications \u2014 basic science (part 1)","author":"Car","year":"2021","journal-title":"Neurol. Neurochir. Pol."},{"key":"10.1016\/j.toxicon.2025.108928_bib9","doi-asserted-by":"crossref","DOI":"10.1002\/mus.21343","article-title":"Assay of diffusion of different botulinum neurotoxin type A formulations injected in the mouse leg","volume":"40","author":"Carli","year":"2009","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.toxicon.2025.108928_bib10","doi-asserted-by":"crossref","first-page":"58","DOI":"10.3390\/toxins13010058","article-title":"Botulinum toxin: an update on pharmacology and newer products in development","volume":"13","author":"Choudhury","year":"2021","journal-title":"Toxins"},{"key":"10.1016\/j.toxicon.2025.108928_bib11","doi-asserted-by":"crossref","DOI":"10.1007\/s00018-004-4293-7","article-title":"Heparan sulfate-protein interactions: therapeutic potential through structure-function insights","author":"Coombe","year":"2005","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.toxicon.2025.108928_bib12","doi-asserted-by":"crossref","DOI":"10.1111\/j.1468-1331.2006.01439.x","article-title":"Immunological aspects of botox\u00ae, dysport\u00ae and MyoblocTM\/NeuroBloc\u00ae","author":"Dressler","year":"2006","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.toxicon.2025.108928_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.toxicon.2010.12.019","article-title":"Studies on the dissociation of botulinum neurotoxin type A complexes","volume":"57","author":"Eisele","year":"2011","journal-title":"Toxicon"},{"key":"10.1016\/j.toxicon.2025.108928_bib14","doi-asserted-by":"crossref","DOI":"10.1007\/s12640-015-9565-5","article-title":"Neutralizing antibody and botulinum toxin therapy: a systematic review and meta-analysis","volume":"29","author":"Fabbri","year":"2016","journal-title":"Neurotox. Res."},{"key":"10.1016\/j.toxicon.2025.108928_bib15","article-title":"Complexing proteins in botulinum toxin type A drugs: a help or a hindrance?","author":"Frevert","year":"2010","journal-title":"Biologics"},{"key":"10.1016\/j.toxicon.2025.108928_bib16","article-title":"Efficacy and safety of LetibotulinumtoxinA in the treatment of moderate and severe glabellar lines in females 35 to 50 years of age: post hoc analyses of the phase 3 clinical study data","volume":"6","author":"Gold","year":"2024","journal-title":"Aesthet Surg J Open Forum"},{"key":"10.1016\/j.toxicon.2025.108928_bib17","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1208\/s12248-024-01003-8","article-title":"Evaluating the immunogenicity risk of protein therapeutics by augmenting T cell epitope prediction with clinical factors","volume":"27","author":"Hu","year":"2025","journal-title":"AAPS J."},{"key":"10.1016\/j.toxicon.2025.108928_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.molstruc.2023.135409","article-title":"Synthesis, molecular docking, and binding gibbs free energy calculation of \u03b2-nitrostyrene derivatives: potential inhibitors of SARS-CoV-2 3CL protease","volume":"1284","author":"Jia","year":"2023","journal-title":"J. Mol. Struct."},{"key":"10.1016\/j.toxicon.2025.108928_bib19","doi-asserted-by":"crossref","first-page":"777","DOI":"10.3390\/ijms26020777","article-title":"Botulinum toxin: a comprehensive review of its molecular architecture and mechanistic action","volume":"26","author":"Kumar","year":"2025","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.toxicon.2025.108928_bib20","doi-asserted-by":"crossref","DOI":"10.3390\/jcm12196326","article-title":"Efficacy, safety, and subject satisfaction of PrabotulinumtoxinA for moderate-to-severe crow's feet: a phase IV, multicenter, double-blind, randomized, placebo-controlled trial","volume":"12","author":"Lee","year":"2023","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.toxicon.2025.108928_bib21","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1111\/j.1468-1331.2006.01652.x","article-title":"Safety and efficacy of botulinum toxin type A following long\u2010term use","volume":"13","author":"Naumann","year":"2006","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.toxicon.2025.108928_bib22","doi-asserted-by":"crossref","DOI":"10.1124\/pr.116.012658","article-title":"Botulinum neurotoxins: biology, pharmacology, and toxicology","author":"Pirazzini","year":"2017","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.toxicon.2025.108928_bib23","doi-asserted-by":"crossref","DOI":"10.1097\/PRS.0000000000008904","article-title":"Botulinum toxin type A immunogenicity across multiple indications: an overview systematic review","author":"Rahman","year":"2022","journal-title":"Plast. Reconstr. Surg."},{"key":"10.1016\/j.toxicon.2025.108928_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.toxicon.2025.108560","article-title":"Targeting the glabellar frown lines with OnabotulinumtoxinA: in-silico evidence supporting concentrated, low-volume injection protocols","author":"Rahman","year":"2025","journal-title":"Toxicon"},{"key":"10.1016\/j.toxicon.2025.108928_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.toxicon.2025.108560","article-title":"Targeting the glabellar frown lines with OnabotulinumtoxinA: in-silico evidence supporting concentrated, low-volume injection protocols","volume":"267","author":"Rahman","year":"2025","journal-title":"Toxicon"},{"key":"10.1016\/j.toxicon.2025.108928_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.toxicon.2025.108548","article-title":"In silico multiscale computational modelling of botulinum toxin A diffusion for glabellar wrinkle treatment: optimizing injection volumes across formulations","author":"Rahman","year":"2025","journal-title":"Toxicon"},{"key":"10.1016\/j.toxicon.2025.108928_bib27","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1007\/s00238-025-02311-8","article-title":"In silico multiscale comparison of LetibotulinumtoxinA and OnabotulinumtoxinA in glabellar line treatment: diffusion dynamics, receptor affinity, and immunologic clearance","volume":"48","author":"Rahman","year":"2025","journal-title":"Eur. J. Plast. Surg."},{"key":"10.1016\/j.toxicon.2025.108928_bib28","doi-asserted-by":"crossref","DOI":"10.3390\/toxins17040182","article-title":"Computational immunogenetic analysis of botulinum toxin A immunogenicity and HLA gene haplotypes: new insights","volume":"17","author":"Rahman","year":"2025","journal-title":"Toxins"},{"key":"10.1016\/j.toxicon.2025.108928_bib29","doi-asserted-by":"crossref","first-page":"182","DOI":"10.3390\/toxins17040182","article-title":"Computational immunogenetic analysis of botulinum toxin A immunogenicity and HLA gene haplotypes: new insights","volume":"17","author":"Rahman","year":"2025","journal-title":"Toxins"},{"key":"10.1016\/j.toxicon.2025.108928_bib30","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1111\/j.1468-1331.2006.01438.x","article-title":"Pharmacology of botulinum toxin: differences between type A preparations","volume":"13","author":"Rosales","year":"2006","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.toxicon.2025.108928_bib31","article-title":"A multicenter, randomized, double-blind, placebo-controlled, single-dose, phase III, non-inferiority study comparing PrabotulinumtoxinA and OnabotulinumtoxinA for the treatment of moderate to severe glabellar lines in adult patients","volume":"40","author":"Rzany","year":"2020","journal-title":"Aesthet Surg J"},{"key":"10.1016\/j.toxicon.2025.108928_bib32","doi-asserted-by":"crossref","DOI":"10.1002\/mds.20021","article-title":"Detection of antibodies against botulinum toxins","author":"Sesardic","year":"2004","journal-title":"Mov. Disord."},{"key":"10.1016\/j.toxicon.2025.108928_bib33","doi-asserted-by":"crossref","DOI":"10.1002\/der2.151","article-title":"Clinical applications and historical perspectives of PrabotulinumtoxinA\u2010xvfs (jeuveau)","volume":"3","author":"Shridharani","year":"2022","journal-title":"Dermatological Reviews"},{"key":"10.1016\/j.toxicon.2025.108928_bib34","doi-asserted-by":"crossref","DOI":"10.5603\/PJNNS.a2021.0028","article-title":"Botulinum toxin type-A preparations are not the same medications - clinical studies (part 2)","author":"S\u0142awek","year":"2021","journal-title":"Neurol. Neurochir. Pol."},{"key":"10.1016\/j.toxicon.2025.108928_bib35","doi-asserted-by":"crossref","DOI":"10.1093\/asj\/sjac210","article-title":"PrabotulinumtoxinA vs OnabotulinumtoxinA for the treatment of adult males with moderate to severe glabellar lines: post-Hoc analyses of the phase III clinical study data","volume":"42","author":"Solish","year":"2022","journal-title":"Aesthet Surg J"},{"key":"10.1016\/j.toxicon.2025.108928_bib36","doi-asserted-by":"crossref","DOI":"10.1007\/s40265-021-01631-w","article-title":"Overview of DaxibotulinumtoxinA for injection: a novel formulation of botulinum toxin type A","volume":"81","author":"Solish","year":"2021","journal-title":"Drugs"},{"key":"10.1016\/j.toxicon.2025.108928_bib37","article-title":"AbImmPred: an immunogenicity prediction method for therapeutic antibodies using AntiBERTy-based sequence features","volume":"19","author":"Wang","year":"2024","journal-title":"PLoS One"},{"key":"10.1016\/j.toxicon.2025.108928_bib38","doi-asserted-by":"crossref","DOI":"10.1016\/S0378-5173(99)00152-0","article-title":"Instability, stabilization, and formulation of liquid protein pharmaceuticals","author":"Wang","year":"1999","journal-title":"Int J Pharm"},{"key":"10.1016\/j.toxicon.2025.108928_bib39","doi-asserted-by":"crossref","DOI":"10.1093\/ajhp\/61.suppl_6.S5","article-title":"Pharmacology of botulinum neurotoxin serotype A","author":"Wenzel","year":"2004","journal-title":"Am. J. Health Syst. Pharm."},{"key":"10.1016\/j.toxicon.2025.108928_bib40","doi-asserted-by":"crossref","DOI":"10.1016\/j.anucene.2018.05.006","article-title":"Monte carlo perturbation methods using \u201cvirtual density\u201d theory for calculating reactivity due to geometry change","volume":"119","author":"Yamamoto","year":"2018","journal-title":"Ann. Nucl. Energy"},{"key":"10.1016\/j.toxicon.2025.108928_bib41","doi-asserted-by":"crossref","DOI":"10.1111\/jdv.17217","article-title":"Randomized, double-blind, active-controlled, multicentre, phase III clinical trial with two stages to assess the safety and efficacy of letibotulinum toxin a vs. onabotulinum toxin a for subjects with moderate to severe crow's feet","volume":"35","author":"Yoo","year":"2021","journal-title":"J. Eur. Acad. Dermatol. Venereol."}],"container-title":["Toxicon"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041010125007032?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041010125007032?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T05:09:15Z","timestamp":1765948155000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0041010125007032"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":41,"alternative-id":["S0041010125007032"],"URL":"https:\/\/doi.org\/10.1016\/j.toxicon.2025.108928","relation":{},"ISSN":["0041-0101"],"issn-type":[{"value":"0041-0101","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"If accessory proteins dissociate, why Don't toxins behave the same? multiscale simulation shows divergent in silico profiles despite an identical core neurotoxin","name":"articletitle","label":"Article Title"},{"value":"Toxicon","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.toxicon.2025.108928","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"108928"}}